Drugs / MVA mBN85B
last change Aug 2010 re-read 2 minutes ago

MVA mBN85B

Vaccine

Developed for
measles
Investigated by
Bavarian Nordic

Trials 1 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00891007 Jun 2009 → Jul 2010 measles Bavarian Nordic Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MVA mBN85B “Two groups will receive two subcutaneous (s.c.) immunizations 4 weeks (28±3 days) apart of either either 1 x 10E7 TCID50 (Group A) or 1 x 10E8 TCID50 (Group B) MVA mBN85B.” NCT00891007
1

NCT00891007

Modality Vaccine “measles vaccine MVA mBN85B” NCT00891007
Route Subcutaneous “two subcutaneous (s.c.) immunizations” NCT00891007